TABLE 4.
Serum 25(OH)D concentrations in relation to clinical outcomes of women undergoing infertility treatment with assisted reproductive technologies1
| Implantation |
Clinical pregnancy |
Live birth |
||||
| Events/cycles, n | Adjusted P2 | Events/cycles, n | Adjusted P2 | Events/cycles, n | Adjusted P2 | |
| Serum 25(OH)D,3 nmol/L | ||||||
| Q1 [65.0 (33.5–75.0)] | 25/45 | 0.51 (0.29, 0.73) | 21/45 | 0.41 (0.22, 0.63) | 15/45 | 0.28 (0.12, 0.52) |
| Q2 [83.1 (75.9–86.2)] | 22/41 | 0.47 (0.28, 0.67) | 21/41 | 0.43 (0.25, 0.63) | 15/41 | 0.26 (0.12, 0.47) |
| Q3 [92.4 (86.8–104.6)] | 28/40 | 0.62 (0.40, 0.81) | 23/40 | 0.48 (0.28, 0.69) | 20/40 | 0.39 (0.19, 0.63) |
| Q4 [115.0 (107.8–155.5)] | 20/42 | 0.43 (0.25, 0.64) | 19/42 | 0.43 (0.25, 0.63) | 16/42 | 0.35 (0.17, 0.57) |
| P4 | 0.71 | 0.83 | 0.47 | |||
1
n = 100 women, 168 cycles. Q, quartile; 25(OH)D, 25-hydroxyvitamin D.
2
Values are predictive marginal means (95% CIs) adjusted for age, BMI, infertility diagnosis, race, dietary patterns, folate, and vitamin B-12 serum concentrations.
3
Values are medians (ranges).
4
The median concentration of vitamin D in each group was used as a continuous variable in the model.